Stellantis’s Carlos Tavares: the hard-driving boss ejected from global carmaker The Guardian Go to Source
Tag: PSA
India’s booming UV market: 32 OEMs, 128 models and 1,001 variants
While it is well known that the utility vehicle (UV) segment, which comprises hatchbacks, sedans, vans and UVs, continues to be the mover and shaker of the overall passenger vehicle segment in India, what’s not known is the real number of UV models and their variants available for sale. And the numbers are truly staggering,… Continue reading India’s booming UV market: 32 OEMs, 128 models and 1,001 variants
Stellantis further delays electric Ram pickup to prioritize plug-in ‘EREV’ model
2025 Ram 1500 Ramcharger Tungsten Ram DETROIT — Stellantis said Wednesday it will further delay an all-electric Ram pickup from 2025 until 2026, as the automaker confronts slower-than-expected adoption of EVs and competitors struggle to make profits on electric trucks. The decision to delay the full battery-electric model, which had already been postponed from this… Continue reading Stellantis further delays electric Ram pickup to prioritize plug-in ‘EREV’ model
Nissan shares notch best day in at least 40 years after reports on potential mega merger with Honda
Makoto Uchida (L), president and CEO of Japanese auto maker Nissan, shakes hands with Toshihiro Mibe (R), director, president and representative executive officer of auto maker Honda, following a press conference in Tokyo on August 1, 2024. Richard A. Brooks | Afp | Getty Images Nissan Motor shares saw a record surge Wednesday following a media… Continue reading Nissan shares notch best day in at least 40 years after reports on potential mega merger with Honda
German FAZ: Stellantis leader with commitment to Opel008399
During the visit to Rüsselsheim on Tuesday, Elkann was accompanied by Xavier Chéreau, who is human resources manager at Stellantis and also chairman of the supervisory board at Opel. Together with Opel boss Florian Huettl, they visited the Astra production in Rüsselsheim and spoke to employee representatives. “At a time of profound industrial changes, I… Continue reading German FAZ: Stellantis leader with commitment to Opel008399
Autocar magazine 18 December: on sale now
In this week’s 148-page Christmas issue we drive a JCB monster truck, compete to build the best Lego car and predict what will happen in the automotive world in 2025. Plus our road testers sit down for their annual Secret Santa lunch and we interview Grand Prix and Le Mans winner Johnny Herbert. Subscribe to… Continue reading Autocar magazine 18 December: on sale now
Tavares says ‘amicable’ Stellantis exit was due to disagreements on strategy – Reuters
Tavares says ‘amicable’ Stellantis exit was due to disagreements on strategy Reuters Go to Source
1.5 BlueHDi diesel engines: “I blame Stellantis for not taking responsibility. Our vehicles are no longer worth anything!”
After PureTech engines, and airbag recalls, the car manufacturer Stellantis has been facing breakage problems on BlueHDI engines for several months. Khaled Benia is concerned. His 3008 no longer runs. It’s been in the garage for months. Company From daily life to major issues, discover the subjects that make up local society, such as justice,… Continue reading 1.5 BlueHDi diesel engines: “I blame Stellantis for not taking responsibility. Our vehicles are no longer worth anything!”
U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn’s disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion’s portfolio, expanding the portfolio and building on Celltrion’s expertise in immunology STEQEYMA is expected to be marketed… Continue reading U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
LUND, Sweden, Dec. 17, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome… Continue reading Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome